搜索
>产品 > CD73

CD73蛋白 - 肿瘤免疫治疗新靶点

背景
CD73是胞外-5'-核苷酸酶,由葡糖基磷脂酰肌醇(GPI)锚定在细胞表面形成同源二聚体,也可被切割并游离于循环系统。CD73有助于将具有免疫激活作用的ATP转化为具有免疫抑制作用的腺苷,肿瘤微环境中的腺苷可以帮助调节性T细胞抑制并关停免疫活性。与调节性T细胞一样,肿瘤细胞也可以表达CD73并释放腺苷,从而降低抗肿瘤活性,抑制CD73可能刺激T细胞的活性。
Nature Medicine发表的一项研究显示 [1] ,野生型和敲除CD73基因的胶质母细胞瘤的两种小鼠模型联合使用PD-1和CTLA-4抑制剂治疗后小鼠的存活率显著提高,且敲除了CD73基因小鼠的存活率明显高于野生型小鼠。研究人员指出抗CD73抗体在临床前和早期的临床研究中都取得了良好的结果,并提出了一种针对胶质母细胞瘤用CD73、PD-1、CTLA-4阻断联合治疗的策略。
ACROBiosystems为抗体药物的开发提供具有高酶活性的CD73靶点蛋白,可有效的降解5'-磷酸腺苷(AMP)成腺苷,经实验测得其酶活高于37,000 pmol/min/μg。另外,CD73蛋白经HPLC、BLI、SPR、ELISA等方法的验证,并免费提供Protocol。
产品列表
Cat. No. Species Tag
CD3-H52H7 Human His tag
CD3-H82E3 Human His Tag & Avi Tag
CD3-M52H9 Mouse His tag
产品验证数据
SEC-HPLC

Fig.1 The purity of Human CD73, His Tag (HPLC-verified) (Cat. No. CD3-H52H7) was greater than 90% as determined by SEC-HPLC.

Protocol

BLI

Fig.2 Loaded Anti-CD73 MAb (Human IgG1) on AHC Biosensor, can bind Human CD73, His Tag (Cat. No. CD3-H52H7) with an affinity constant of 0.179 nM as determined in BLI assay (ForteBio Octet Red96e).

Protocol

SPR

Fig.3 Anti-CD73 antibody (Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface can bind Human CD73, His Tag, HEK293 (Cat. No. CD3-H52H7) with an affinity constant of 0.164 nM as determined in SPR assay (Biacore 8K).

Protocol

ELISA

Fig.4 Immobilized Human CD73, His Tag (HPLC-verified) (Cat. No. CD3-H52H7) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human CD73 Antibody, Human IgG1 with a linear range of 0.15-5 ng/mL.

Protocol

*如果您希望ACRO开发更多类型的CD73蛋白产品, 请 点击提议
*如果您希望ACRO补充更多CD73蛋白产品的实验设计和应用数据,请 点击咨询

消息提示

请输入您的联系方式,再点击提交!

确定